Answers are grounded in this paper and cite their sources.
Spatial transcriptomics (ST) has deepened our understanding of cellular spatial heterogeneity, yet existing technologies are predominantly confined to fixed or frozen specimens, limiting longitudinal molecular profiling of the same living tissue. To overcome this limitation, we developed LIFE-seq (Living-tissue in situ nanoforest extraction for spatiotemporal transcriptomic mapping), a minimally invasive approach that combines high-density nanoforest arrays for molecular sampling with directed transfer onto spatially barcoded messenger RNA (mRNA) capture chips. LIFE-seq enables spatial transcriptomic profiling while preserving overall tissue integrity and provides a modular strategy with the potential to integrate different 3'-end capture platforms. Performance validation demonstrated high concordance in global transcriptomic profiles and spatial gene expression patterns between nanoforest-derived replicas and conventional tissue sections, as well as faithful recapitulation of pathological features in a traumatic brain injury (TBI) model. Furthermore, longitudinal spatial transcriptomic profiling of cortical injury in the same mouse revealed temporally distinct injury responses, progressive activation of immune-associated gene programs, and spatially heterogeneous cell-type-specific expression changes. By enabling repeated molecular sampling and spatial transcriptomic analysis of living tissue, LIFE-seq provides a versatile framework for investigating tissue dynamics and pathological progression in vivo.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: